RENXF Renalytix plc

RENXF financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1811115 Exchange: OTC SIC: 8071 (Services-Medical Laboratories) Latest filing: 10-Q filed Nov 19, 2024 Data checked: Oct 21, 2026
Showing 3 of 6 annual and 0 of 9 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
<br>Emerging growth company
Entity Type
Operating
Public Float
$24.71M (Dec 2023)
Industry (SIC)
8071 Services-Medical Laboratories
Incorporated
X0
Fiscal Year End
June (0630)
Phone
44 29 2071 0570
EIN
000000000
Headquarters
LONDON
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Renalytix AI plc (2020–2021)

▼ Key Metrics (TTM)

As of Sep 30, 2024
Financials
Revenue
$2.35M
Net Income
$-28.03M
Total Assets
$4.79M
Total Equity
$-11.32M
Total Debt
-
Free Cash Flow
-
Ratios
Gross Margin
12.7%
Operating Margin
-1054.9%
Net Margin
-1191.8%
Return on Equity
247.6%
Return on Assets
-584.7%
Current Ratio
0.24x

▼ FY 2024 Summary Analysis

Annual report ending Jun 30, 2024

Overview and Growth

Fiscal 2024 results for Renalytix plc combined $2.29M of revenue with net loss of $33.46M and an operating cash outflow of $30.11M. The $2.29M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Compared with $3.40M in fiscal 2023, revenue decreased 32.7%, a top-line contraction that reduced operating scale. The company reported diluted EPS of -$0.31, adding a shareholder-level measure to the absolute income figures considered below. A diluted share base of 108.18M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Compared with 82.21M diluted shares in fiscal 2023, the current 108.18M base was 31.6% higher. Total assets stood at $7.97M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Asset turnover was 0.29x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

After reported cost of revenue, the company retained $156.00K as gross profit before recognizing operating expenses and other items. Gross profit represented 6.8% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $29.61M, reflecting costs that exceeded gross profit. The bottom-line result was a net loss of $33.46M after operating, financing, tax, and other recognized items. EBITDA was negative $29.24M, showing a deficit before interest, taxes, depreciation, and amortization. Before income taxes, the company recorded a loss of $33.45M, bridging the operating result to the final net loss. The reported income-tax provision was $4.00K, the amount recognized between pretax income and the final net-income result. The net loss equaled 419.7% of period-end assets, showing the deficit relative to the asset base. The net loss narrowed to $33.46M from $45.61M in fiscal 2023.

Liquidity and Capital Structure

The company held $7.97M of assets against $15.83M of liabilities and -$7.85M of equity, revealing how the asset base was financed. The company reported negative equity of -$7.85M, a capital deficit that reduces its ability to absorb losses through book equity. At period end, current assets of $6.12M compared with current liabilities of $11.49M, defining the company’s short-term resource position. Current assets covered only 0.53x of current liabilities, so current liabilities exceeded current assets at period end. Reported cash and equivalents were $4.68M, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 40.7%, excluding receivables and other current assets. Equity equaled -98.5% of assets, showing the shareholder-capital layer within the company’s balance sheet. Liabilities represented 198.5% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 58.7% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 74.0% from $30.63M in fiscal 2023, leaving current total assets lower year over year. Against $6.97M of equity in fiscal 2023, the current book-equity balance moved 212.7% and ended lower. Cash and equivalents were 81.0% lower than fiscal 2023 cash of $24.68M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $30.11M, showing that operations absorbed cash during the period. The operating cash outflow narrowed to $30.11M from $34.09M in fiscal 2023.
Based on the annual report for the fiscal year ending Jun 30, 2024. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Renalytix plc
Metric FY2024 📄 FY2023 📄 FY2022 📄
Income Statement
REVENUE
Revenue $2.29M $3.40M $2.97M
Cost of Revenue $2.13M $2.68M $2.10M
Gross Profit $156.00K $720.00K $874.00K
OPERATING EXPENSES
R&D Expense $9.29M $14.30M $14.65M
SG&A Expense $19.75M $28.66M $39.52M
Other Operating Expenses (derived) $723.00K $-19.00K $-115.00K
Operating Income $-29.61M $-42.22M $-53.18M
NON-OPERATING INCOME / EXPENSE
Other Income/Expense $249.00K $656.00K -
Pretax Income $-33.45M $-45.61M $-45.25M
Income Tax $4.00K $2.00K $25.00K
Net Income $-33.46M $-45.61M $-45.28M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.31 $-0.55 $-0.67
Diluted Shares 108.18M 82.21M 73.84M
EBITDA $-29.24M $-41.71M $-52.69M
Depreciation & Amortization $364.00K $508.00K $489.00K
Balance Sheet
ASSETS
Cash & Equivalents $4.68M $24.68M $41.33M
Accounts Receivable $722.00K $776.00K $901.00K
Other Current Assets $716.00K $1.42M $2.45M
Current Assets $6.12M $26.88M $44.75M
PP&E (Net) $216.00K $1.03M $2.56M
Intangible Assets $869.00K $1.05M $1.19M
Other Noncurrent Assets $940.00K $1.10M -
Noncurrent Assets $1.85M $3.75M $5.31M
Total Assets $7.97M $30.63M $50.07M
LIABILITIES
Accounts Payable - - $1.38M
Other Current Liabilities $178.00K $10.00K $12.00K
Current Liabilities $11.50M $16.14M $11.78M
Noncurrent Liabilities $4.33M $7.53M $7.68M
Total Liabilities $15.83M $23.66M $19.46M
EQUITY
Common Stock $478.00K $286.00K $228.00K
Additional Paid-in Capital $204.89M $186.46M $164.01M
Retained Earnings $-211.78M $-178.33M $-132.72M
Accumulated OCI $-1.44M $-1.45M $-915.00K
Total Equity $-7.85M $6.97M $30.61M
Total Liabilities & Equity $7.97M $30.63M $50.07M
SUPPLEMENTAL
Shares Outstanding 154.37M 93.78M 74.76M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-30.11M $-34.09M $-45.92M
Capital Expenditures - $0 $557.00K
Cash from Investing $-4.00K $0 $-662.00K
Cash from Financing $10.25M $16.39M $25.63M
Free Cash Flow - $-34.09M $-46.48M
Beginning Cash (CFS) $24.68M $41.33M $65.13M
Net Change in Cash $-19.87M $-17.70M $-20.96M
Effect of FX on Cash $-137.00K $1.05M $-2.84M
Calculated Ending Cash $4.68M $24.68M $41.33M
Cash per BS $4.68M $24.68M $41.33M
Cash scope difference (CFS − BS) - - -
Cash per CFS $4.68M $24.68M $41.33M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Renalytix plc's annual revenue?

Renalytix plc reported $2.35M in revenue for trailing twelve months (ending September 2024). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Renalytix plc profitable?

No. Renalytix plc reported $-28.03M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.